You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》美銀證券下調翰森製藥(03692.HK)目標價至10.18元 評級「跑輸大市」
阿思達克 08-16 09:56
美銀證券發表報告指,因應內地近期的醫藥反貪腐措施,下調翰森製藥(03692.HK)2024至2025年的產品收入預測,目標價由11.9元下調至10.18元,維持「跑輸大市」評級。 該行更新翰森製藥6月份銷售情況,當中甲磺酸阿美替尼片(almonertinib)、甲磺酸氟馬替尼片(flumatinib)、聚乙二醇洛塞那(月太)(PEG-loxenatide)、艾米替諾福韋片(tenofovir amibufenamide)及恩雜魯胺(Enzalutamide)的銷售額,分別為1.43億、3,470萬、3,030萬、3,140萬及690萬元人民幣(下同),按年各增長45.1%、51.3%、97.5%、106.8%及370.9%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account